Publication | Open Access

396MO Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase I study

Anti-claudin 18.2Esophageal CancerGastrointestinal OncologyMedicineAntibody-drug ConjugateImmunologyPathologyCancer TreatmentOncologyG/gej AcCancer ResearchMolecular Oncology